Filtered By:
Therapy: Immunotherapy
This page shows you your search results in order of relevance.
Order by Relevance | Date
Total 258 results found since Jan 2013.
siRNA therapeutics for breast cancer: recent efforts in targeting metastasis, drug resistance, and immune evasion.
Abstract
Small interfering RNA (siRNA) has an established and precise mode of action to achieve protein knockdown. With the ability to target any protein, it is very attractive as a potential therapeutic for a plethora of diseases driven by the (over)expression of certain proteins. Utilizing siRNA to understand and treat cancer, a disease largely driven by genetic aberration, is thus actively investigated. However, the main hurdle for the clinical translation of siRNA therapeutics is to achieve effective delivery of siRNA molecules to tumors and the site of action, the cytosol, within cancer cells. Several nanopar...
Source: Translational Research : the journal of laboratory and clinical medicine - August 18, 2019 Category: Laboratory Medicine Authors: Ngamcherdtrakul W, Yantasee W Tags: Transl Res Source Type: research
Construction of PEI ‐EGFR‐PD‐L1‐siRNA dual functional nano‐vaccine and therapeutic efficacy evaluation for lung cancer
ConclusionOur constructed lipid nanoparticles of tumor targeted therapy gene siRNA combination had the ability to target cells in vitro and downregulate the expression of PD-L1, realizing the tumor-specific expression of immune-stimulating cytokines, which is a highly efficient and safe targeted therapy nano-vaccine.
Source: Thoracic Cancer - September 19, 2022 Category: Cancer & Oncology Authors: Guixue Yang,
Dong Zhou,
Yin Dai,
Yanqi Li,
Jiang Wu,
Quanxing Liu,
Xufeng Deng Tags: ORIGINAL ARTICLE Source Type: research
Targeted Delivery of siRNA Therapeutics Using Ligand Mediated Biodegradable Polymeric Nanocarriers.
CONCLUSION: In this review, we provide ⅰ) an overview of the non-viral carrier associated with siRNA delivery for cancer treatment, and ⅱ) a description of the five major cancer-targeting ligands.
PMID: 29962332 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Design - July 1, 2018 Category: Drugs & Pharmacology Authors: Jin HS, Soo CK, Hye AM, Sukdeb P, Pill-Hoon C, Sangshetti J, Arote RB Tags: Curr Pharm Des Source Type: research
TLR9-Targeted SiRNA Delivery In Vivo.
Abstract
The SiRNA strategy is a potent and versatile method for modulating expression of any gene in various species for investigational or therapeutic purposes. Clinical translation of SiRNA-based approaches proved challenging, mainly due to the difficulty of targeted SiRNA delivery into cells of interest and the immunogenic side effects of oligonucleotide reagents. However, the intrinsic sensitivity of immune cells to nucleic acids can be utilized for the delivery of SiRNAs designed for the purpose of cancer immunotherapy. We have demonstrated that synthetic ligands for the intracellular receptor TLR9 can serve...
Source: Mol Biol Cell - October 17, 2015 Category: Molecular Biology Authors: Hossain DM, Moreira D, Zhang Q, Nechaev S, Swiderski P, Kortylewski M Tags: Methods Mol Biol Source Type: research
Immunotherapy with a biologically active ICAM-1 mAb and an siRNA targeting TSHR in a BALB/c mouse model of Graves' disease
Conclusions These preliminary data suggest that both the biologically active ICAM-1 mAb and the siRNA targeting TSHR were effective. The ICAM-1 mAb exerted a better therapeutic effect than the siRNA targeting TSHR. Both treatments showed potential efficacy as novel treatments for GD and may therefore represent therapeutic options in addition to the existing drugs or interventions.PMID:34647608 | DOI:10.5603/EP.a2021.0087
Source: Endokrynologia Polska - October 14, 2021 Category: Endocrinology Authors: Xuan Wang Wei Liu Zhongying Rui Wei Zheng Jian Tan Ning Li Yang Yu Source Type: research
